Targacept Articles
Senior appointments at Sanofi, Shire and Targacept; Global Fund names new executive director, fires inspector general
16 November 2012
Targacept ADHD candidate fails to meet primary endpoints in Ph II study
18 September 2012
Double R&D setback for AstraZeneca; new deal for cancer candidate
21 December 2011
Disappointment for AstraZeneca and Targacept as antidepressant fails to meet Ph III endpoint
9 November 2011
GlaxoSmithKline pulls out of Targacept alliance
4 March 2011
Targacept slides as ADHD drug under development with AstraZeneca disappoints in Ph II
8 October 2010
Unipolar depression drug market set to decrease by nearly 10% in 2019 due to generic erosion
12 August 2010
AstraZeneca and Targacept initiate Ph III development of TC-5214 as adjunct treatment for major depressive disorder
24 June 2010
Showing 1-16 of 16 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
